LUNG CANCER

Treatment of NSCLC With Uncommon EGFR Mutations

The new drug application for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that harbor an NTRK gene fusion has been completed. 

The treatment landscape of non-small cell lung cancer has been identifying the importance of immunotherapy already, but combination therapies will soon play a large role in treatment of these patients as well, according to Chad Pecot, MD.

According to findings from the phase III IMpower150 trial, significant improvement was found in overall survival with a treatment regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared to the combination of bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer. 

According to topline findings from the phase III IMpower131 trial, the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer. These results were released by Genentech, the manufacturer of the anti–PD-L1 agent.

Lung Cancer

After reviewing data from a decade of clinical research, a joint panel from ASCO and the College of American Pathologists concluded that circulating tumor DNA testing should be used only to screen for participation in, or during, a clinical trial.

In an interview with<em> Targeted Oncology</em>&nbsp;ahead of the 5th Annual Miami Lung Cancer Conference,&nbsp;Sarah B. Goldberg, MD, discusses&nbsp;the key points of her lecture on testing for and treating resistance to EGFR TKI therapy in NSCLC.